Finally, the lack of detailed reasons for redialysis or mortality also constrains the depth of our outcome analysis, In summary, our observations suggest that GLP-1 RAs may be associated with a reduction in the risk of mortality, MACEs, and MAKEs in patients with type 2 diabetes following severe AKI, over a median follow-up of 2.3 years
Our full integration of BPC-157 into a personalized peptide protocol is detailed on our Peptide Treatment Plan page at Perfect B in Miami, which explains how we select and stack peptides for each patients goals
When youre on a GLP-1, hydration matters more than ever
[DOI] [PubMed] [Google Scholar] 128.Majumder K., Chakrabarti S., Morton J.S., Panahi S., Kaufman S., Davidge S.T., Wu J.P